GCG and obesity disorder: Indeed, evidence from preclinical studies suggests that in addition to suppressing food intake, liraglutide, which is a stable analog of the gut hormone glucagon-like peptide 1 (GLP-1) and 1 out of 5 currently approved obesity pharmacotherapies by the FDA (68), increases energy expenditure through stimulatory effects on BAT and BeAT thermogenesis (69, 70).